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Abstract 
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very attractive in diverse applications in the fields of health, clean and renewable energy, and 
environmental sustainability. This article comprehensively summarizes state-of-the-art fluorescence 
imaging using ultra-small nanoparticles as probes, including quantum dots, metal nanoclusters, carbon 
nanomaterials, up-conversion, and silicon nanomaterials. 
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5  The novel optical, electrical, and magnetic properties of ultra-small inorganic nanoparticles make them 
very attractive in diverse applications in the fields of health, clean and renewable energy, and 
environmental sustainability. This article comprehensively summarizes state-of-the-art fluorescence 
imaging using ultra-small nanoparticles as probes, including quantum dots, metal nanoclusters, carbon 
nanomaterials, up-conversion, and silicon nanomaterials. 
 
10  1 Introduction 
 
When the size of inorganic materials is reduced to the nanoscale 
range, they exhibit unusual optical, electrical, magnetic, 
mechanical, and chemical properties, distinctly different from 
those  in  their  bulk  analogues.  For  example,  semiconductor 
15  nanocrystals (usually referred to as quantum dots (QDs)) exhibit 
strong size-dependence of their optical properties when their size 
is smaller than the Bohr exciton radius.1 Magnetic iron oxide 
nanoparticles become superparamagnetic when their size is 
reduced below the critical size where they behave as individual 
20  magnetic domains.2  Carbon nanotubes show remarkable tensile 
strength,3 and graphene exhibits remarkably high electron 
mobility.4  Their novel properties make these nanomaterials very 
attractive in diverse applications, ranging from energy conversion 
and storage to biomedical imaging. In this article, we summarize 
25 the recent advances in ultra-small inorganic nanoparticles for 
fluorescence imaging (Table 1), especially those smaller than 10 
nm as they are easily taken up and excreted, and show longer 
blood circulation time in comparison with larger ones. 
For fluorescent materials, there are two kinds of 
30 photoluminescence mechanisms, i.e. down conversion and up 
conversion.5 The down-conversion process normally absorbs one 
high energy photon and emits a low energy photon, e.g. a Stokes- 
shift  emission.  In  contrast,  up-conversion  is  an  anti-Stokes 
process that converts the absorbed low energy light into higher 
35 energy emission via multiple absorptions or energy transfer 
processes. The fluorescence generated by both processes has long 
been used in molecular imaging to visualize cell biology at many 
levels.6, 7  The first fluorescence imaging could be dated back to 
1924 when Policard observed red fluorescence from endogenous 
40  porphyrins in tumours illuminated with an ultraviolet light.8 Since 
then, advances in molecular biology, organic chemistry and 
material  science  have  revealed  several  classes  of  promising 
probes for fluorescence imaging, which include small organic 
dyes,     fluorescent     proteins,     and     fluorescent     inorganic 
45  nanoparticles.6   Compared  with  organic  dyes  and  fluorescent 
proteins, fluorescent inorganic nanoparticles have several distinct 
advantages. For example, QDs have high absorbance, high QY, 
narrow  emission,  large  Stokes  shifts,  and  high  resistance  to 
 
 
photobleaching.9     These   properties   render   them   robust   for 
50 fluorescent probes for biolabelling and bioimaging.9-12 In recent 
years, other fluorescent nanomaterials, such as ultra-small metal 
nanoclusters, fluorescent carbon and graphene dots, up- 
conversion nanocrystals, and silicon nanoparticles have been 
exploited as alternatives to conventional QDs. In the following 
55 sections, we introduce these fluorescent  nanomaterials  from 
viewpoints of preparation and functionalization to satisfy the 
requirements  for  routine  labelling  and  imaging  of  cells  and 
tissues. Advanced applications of fluorescent nanomaterials in 
living systems as sensors for enzyme, oxygen, metal ions, and 
60  pH, have readily been described elsewhere.13-16 
For bioimaging, fluorescent nanoparticles should have water- 
solubility, biocompatibility, chemical- and photo-stability. They 
should also have uniform size and high quantum yield (QY) for 
optimized   brightness,   narrow   and   symmetric   emission   for 
65 multiplexing and colour saturation, and minimized blinking for 
light output stability. In the second part, we introduce the 
development in synthesis and surface modification of fluorescent 
QDs (especially CdSe- and CdTe based II-VI QDs) to result in 
water-soluble, biocompatible and highly stable QDs with high 
70  QY, together with their routine bioimaging applications and their 
toxicity. In the third section, we describe extremely small metal 
nanoclusters (usually smaller than 2 nm) as an emerging 
fluorescent probes, and address the difficulties in their synthesis, 
characterization,  modification,  and  imaging  application.  In  the 
75 fourth part, we bring in carbon-based fluorescent nanoprobes 
including carbon dots and graphene quantum dots (GQDs), which 
are usually smaller than 10 nm. These carbon-based nanoprobes 
have excellent biocompatibility and unique properties (e.g. both 
up-conversion  and  down-conversion  emissions).  In  the  fifth 
80 section, we briefly introduce lanthanide-based up-conversion 
nanocrystals,  which  have  attracted  considerable  attention  in 
recent years. Most of up-conversion nanoprobes have a large size 
(>10 nm) and are out of the scope of this article. In the sixth part, 
we discuss fluorescent silicon nanoparticles, which have excellent 
85 biocompatibility and stability. In the last part, we highlight the 
major  challenges  and  perspectives  of  ultra-small  fluorescent 
 
Types Representatives Preparation Size (nm) Advantages Disadvantages Applications 
QDs CdSe, CdTe, InP, 
CuInS2, CuInSe2, 






< 10 Tuneable size and 
fluorescence, 
high QY and 
relatively stable 
toxicity Fluorescent labels 
and sensors 
Metal NCs Au, Ag, Cu, Pt, Pd Reduction of metal 
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large metal 
nanoparticles 
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drug carriers 
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NH4Br                                                                                                                           
< 5 Small size, Ultrahigh 
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nanoparticles and fluorescence bioimaging. 
 




























QDs: quantum dots; UCNs: up-conversion nanocrystals; NPs: nanoparticles; GQDs: graphene quantum dots; QY: quantum yield 
 
 
2 Semiconducting Fluorescent QDs 
 
5  2.1 Synthesis of monodisperse QDs with high QYs 
 
Fluorescent QDs include semiconducting nanoparticles from 
Groups IV (Si and Ge dots),17-20 II-VI (CdE and ZnE, E = S, Se, 
and Te), III-V (InP), and I-III-VI (CuInS2, CuInSe2),
21-23 in which 
the II-VI QDs (especially CdSe and CdTe based QDs) have been 
10  extensively investigated as prototypes of semiconductor QDs due 
to  their  strong  quantum  confinement  effects  and  high 
fluorescence  QYs.   II-VI  colloidal   fluorescent  QDs  can  be 
prepared in organic solvents or aqueous solutions. Organic routes 
are   usually   selected   to   prepare   monodisperse   and   highly 
15 fluorescent QDs. Discovered in 1981, QDs did not receive 
intensive  attention  until  1993,  when  a  breakthrough  in 
preparation   of   colloidal   QDs   in   solution   was   achieved.24 
Monodisperse cadmium chalcogenide (CdE, E = S, Se, and/or Te) 
QDs   were   prepared   by   fast   injection   of   a   solution   of 
20 precursors  (organometallic  Cd  and  Se/S/Te  dissolved  in 
trioctylphosphine (TOP)) into a high-boiling-point (~ 300 °C) 
coordinating   solvent   trioctylphosphine   oxide   (TOPO). 24 
These QDs had a narrow particle size distribution with 10% 
standard  deviation,  which  was  reduced  to  5%  after  size- 
25  selective precipitation. Their fluorescent QY was about 10%. 
The key in this “TOPO-TOP” approach is a burst of 
nucleation   which   can   be  effectively  separated   from   the 
growth process.25  The use of highly flammable and toxic 
dimethylcadmium, however, limited the applicability of this 
30 approach at that time. Extensive efforts have been made to 
develop and optimize this approach by using various stable 
and  low  toxicity  precursors26   (e.g.  cadmium  oxide,  CdO; 
cadmium  carboxylate,  Cd(OOCR)2;  selenium  oxide,  SeO2, 
etc.),  non-coordinating  solvents  (e.g.  1-octadecene,  ODE) 
35 and     stabilizers27        (e.g.     octyldiphenylamine     (ODPA), 
diethylenetriaminepentaacetic  acid  (DTPA),  hexadecyl  amine 
(HDA), etc.) to generate monodisperse QDs with high QY. 
Monodisperse II-VI QDs with different sizes and shapes can 
be obtained by controlling their nucleation and growth processes 
40 through optimization of monomer concentration and reactivity, 
molar ratio, reaction temperature, ligands, etc. (Figure 1).28-31  It 
has been found that slight modification of reaction parameters 
can lead to a broad variety of particle sizes and shapes. For 
example,  Peng  et  al.  demonstrated  that  the  size  and  size 
45 distribution of CdSe dots can be manipulated by the monomer 
concentration.32 At high monomer concentrations, the smaller 
nanoparticles grow faster than larger ones, which results in the 
size distribution being “focused”. If the monomer concentration 
drops below a critical threshold, the smaller particles are depleted 
50 as  larger  ones  grow  (i.e.  Ostwald  ripening),  and  the  size 
distribution gets broader or is “defocused”. Controlling the 
nanoparticle growth kinetics can result in a narrow particle size 
distribution  (5%  standard  deviation)  without  the  size- 
selective precipitation.32 
55  It was observed that the QY increased monotonically to 
the  maximum  value  and  then  decreased  with  the  growth 
time.33 Such a photoluminescence bright point indicates an 
optimal surface structure/reconstruction. Use of a large Se/Cd 
ratio (10/1) can result in very bright CdSe QDs with QY of 
60  85%  at  room  temperature.  The  high  QY  of  these  QDs  is 
attributed to stabilization of organic ligands on the surface. Since 
these ligands can be chemically degraded and detached from the 













Figure 1. Transmission electron microscope (TEM) images 
and growth paths of CdSe nanocrystals with different 


















Figure 2. TEM images and blinking behaviour of core-shell 
CdSe@CdS nanoparticles: (a) 2.2 nm CdSe core with 2.4 nm 
CdS shell; (b) 2.2 nm CdSe core with 0.7 nm CdS shell. 
Reproduced from Ref. 36. 
sometimes severely affected. In order to improve their 
luminescence and photostability, wide-band-gap shells (e.g. 
cadmium sulphide (CdS) and zinc sulphide (ZnS)) have been 
coated onto their surface to form core-shell QDs.34, 35  Li et al. 
5  developed   a   successive   ion   layer   adsorption   and   reaction 
(SILAR) technique to epitaxially grow shells in a non- 
coordinating solvent.34  The resultant core-shell CdSe@CdS QDs 
had a QY of 40%. Xie and his co-workers further developed 
this approach to prepare CdSe-core-multishell QDs with QY 
10  up to 85%.35  Recently, Chen et al. used cadmium oleate and 
octanethiol as Cd- and S-precursors, and prepared nearly 
perfect  core-shell  CdSe@CdS  QDs  with  the  highest  QY 
(97%)   ever   reported   (Figure   2). 36    The   slow  continuous 
precursor   infusion   and   the   relatively   low   reactivity   of 
15  octanethiol provide optimal condition s for passivation of the 
CdSe surface and growth of the CdS shell. Compared with 
conventional core-shell CdSe@CdS QDs, these new QDs 
featured significantly suppressed blinking, with an average 
fluorescence on/off time ratio of 94:6 for single large core - 
20 shell nanocrystals (Figure 2). The blinking was gradually 
suppressed with increasing shell thickness.36 In addition to 
Wurtzite core-shell CdSe@CdS QDs, zinc-blende core-shell 
analogues  with  suppressed  blinking  (>95%  on  time)  were 
also  prepared  by  Qin  and  co-workers.37   These  zinc  blende 
25  core-shell CdSe@CdS QDs exhibited a QY of 90%. It should 
be noted that non-blinking core-shell CdZnSe@ZnSe QDs, 
which exhibited complete suppression of blinking on the time 
scale from milliseconds to hours, were successfully prepared 
 
by Wang et al.38  The high fluorescence QY and non-blinking 
30 QDs  make  them very useful  in  applications requiring  a 
continuous output of single photons. 
During the preparation of QDs, attempts to adjust the growth 
kinetics of the QDs incidentally led to the development of one- 
dimensional  (1D)  nanorods.29   By  using  very  high  precursor 
35  concentrations and a defined admixture of alkylphosphonic acids 
and trioctylphosphine oxide (TOPO), 1D and even more complex 
structures  such  as  arrows,  teardrops,  or  tetrapods  were 
synthesized (Figure 1).30 Recently, we demonstrated that doped 
and undoped 1D semiconductor nanostructures can be produced 
40 by using a lower precursor concentration in the presence of 
bismuth nanoparticles.39-44  This is in contrast to the synthesis of 
1D nanostructures without nanocatalysts. These nanowires 
exhibited unusual optical,45, 46 electronic,47, 48 and magnetic40 
properties  with  potential  diverse  applications.48,   49    The  fast 
45 growth process resulted in crystal twinning and defects in the 
nanowires,50, 51  leading to a low fluorescence QY (< 1%) which 
could be improved by more than three times through coating with 
a wide-band-gap shell.52 
Despite monodispersity, high QY, and stability, these QDs 
50 generated in organic solvents are normally hydrophobic and 
have to be modified in order to be water-soluble and 
biocompatible for bioapplications. The modification leads to 
the  decrease  in  fluorescence  QY,  e.g.  the  QY  of  above 
perfect  core-shell  CdSe@CdS  QDs  decreased  from 94%  to 
55  77%  after  transferred  into  PBS  solution  with  PEG-SH.36 
Therefore, direct preparation of QDs in aqueous solution has 
been developed almost simultaneously. 
The aqueous approach was firstly adopted by Henglein et 
al. to prepare CdS nanoclusters in 1982.53  They also reported 
60  the first example of the preparation of CdTe QDs in aqueous 
solution.54   The  resultant  CdTe  QDs  did  not  show 
fluorescence, however. Rogach et al. synthesized stable 
fluorescent CdTe QDs with a QY of 3% by using thioglycerol 
and mercaptoethanol as stabilizers. 55  Later on, many efforts 
65  were   made   to   improve   QD   fluorescence   QY   by   using 
different stabilizers (thioglycolic acid (TGA); 
mercaptopropionic  acid  (MPA)),  precursor  ratios,  and 
manners  of  heating  (hydrothermal  and  microwave 
methods).56  Under the optimal conditions, the QY of water - 
70  soluble CdTe-based QDs can reach as high as 84%, which is 
comparable to that of the above-mentioned hydrophobic QDs. 
High fluorescence QY also can be obtained by surface 
modification of as-synthesized QDs with illumination. For 
example, the fluorescence QY of CdTe QDs was drastically 
75  improved from 8% to 85% after 28 -day illumination, due to 
the  formation  of  the  core-shell  structure  (i.e.  CdTe@CdS) 
with the assistance of illumination.57 
The above water-soluble QDs were normally prepared in 
strong   basic   solution   (pH   >   8),   which  limits  their  bio- 
80  applications,  as  most  biological  activities  take  place  under 
neutral-pH conditions. Adjusting the solution pH to neutral could 
quench the fluorescence of the QDs. Therefore, it is of great 
interest to develop a novel approach for preparing highly 
fluorescent  water-soluble  QDs  from  stable  precursors  under 
85 neutral   pH   conditions.   Recently,   we   have   successfully 



















Figure  3.  Tunable  core-shell  CdTe@CdS  QDs  with  high 
stability. Reproduced from Ref. 58. Figure 4. Preparation of sandwich-like SiO2@CdTe@SiO2 
nanoparticles for cell labeling. Reproduced from Ref. 72. 
(MSA)-capped CdTe/CdS QDs using stable Na2TeO3  as the Te 
source via a one-pot reaction under neutral conditions (Figure 
3).58   A  novelty  of  this  approach  is  the  use  of  MSA,  which 
exhibits the features (pKCOOH1  = 3.30, and pKCOOH2  = 4.94) of 
5  both TGA (pKCOOH = 3.53) and MPA (pKCOOH = 4.32) in terms of 
acidity. MSA can effectively stabilize QDs in a wider pH range 
(pH = 6 – 9) with better protection because of its stronger 
interactions with the surface Cd2+ ions and its stronger steric 
effects. In addition, slow decomposition of MSA-Cd complexes 
10  forms a thin layer of CdS on the surface of CdTe nanocrystals, 
decreasing the surface defects and leading to high fluorescence 
QY. Another novelty is the use of sodium citrate as buffer. The 
resultant QDs show higher fluorescence QY than those stabilized 
with  TGA  or  MPA  obtained  from  the  conventional  aqueous 
15 method.   They   also   show   lower   cytotoxicity   at   certain 
concentrations due to the unique structure of MSA and the 
formation of a CdS shell on the surface of the CdTe core.58 
In  addition  to  organic  and  aqueous  routes,  QDs  can  be 
produced in living organisms. Stürzenbaum et al. demonstrated 
 
dihydrolipoic acid (DHLA) are often used. Unfortunately, ligand- 
exchange can lead to a huge loss of fluorescence due to the 
changes  in  surface  properties.  These  small  molecules  cannot 
45  prevent QDs from oxidation and degradation. Thereby a number 
of polymers (e.g. polyethylene glycol (PEG), and 
polyethylenimine (PEI)), proteins, peptides, and liposomes have 
been adopted to coat QDs.12  Similar to small-molecule modified 
QDs, these surface-coated  flexible polymers and  biomolecules 
50  are less resistant to oxygen and chemicals, and have little impact 
on the improvement of the photo- and chemical stability of QDs. 
Therefore, organic-modified QDs still face the issues of toxicity, 
instability and the loss of fluorescence, despite the significant 
progress achieved in recent years. 
55  Compared  with  unmodified  and  organically  modified  QDs, 
QDs coated with an inorganic shell show higher stability in terms 
of both chemistry and fluorescence. Silica is one of the most 
popular inert materials used for surface modification, and has a 
few distinct advantages,65 including: (1) a non-porous silica shell 
20  that  the  earthworm’s   metal  detoxification   pathway  can   be 
exploited to produce water-soluble and biocompatible CdTe 
QDs.59  This bioapproach is time-consuming (11 days), however, 
and the resultant QDs have a low fluorescence QY (8%), so this 
method cannot be used for large-scale preparation. 
 
25  2.2 Surface modification of QDs 
 
From   the   viewpoint   of   bioapplications,   QDs   should   have 
excellent water-solubility, biocompatibility, and stability. These 
properties not only depend on their particle size, shape and 
composition, but also rely on their surface structure and surface 
30  charge.   More   importantly,   the   surface   properties   of   QDs 
determine  their  bio-interface  interactions,  cellular  endocytosis 
and intracellular distribution, in vivo biodistributions, metabolism, 
and  fate.60-63   Engineering  surface  of  QDs  therefore  becomes 
highly important as this process can improve these properties and 
35  introduce   additional   functions.10     Medintz   et   al.   recently 
summarized the strategies for surface modification and 
bioconjugation of QDs.11 One popular strategy for hydrophobic 
QDs is ligand exchange, which not only transfers them from 
organic   solvents   into   aqueous   solution,   but   also   provides 
40  functional  groups  for  further  conjugation  with  biomolecules.64 
Small   water-soluble   molecules   such   as   TGA,   MPA,   and 
60  can protect QDs from environmental damage and improve their 
stability;66 (2) the silica shell can effectively inhibit the release of 
toxic Cd2+ ions and thus reduce the QDs’ toxicity;66 (3) the silica 
coating can provide a hydrophilic surface and functional groups 
for  conjugating  with  biomolecules.67   The  silica  shell  can  be 
65  formed on the surface of the QDs by the Stöber method68  or the 
reverse microemulsion approach.69 Both methods have their own 
advantages and disadvantages, but one common challenge is the 
preparation of highly fluorescent QDs@SiO2  nanoparticles with 
tuneable size, as the fluorescence of QDs is drastically decreased 
70  during silica coating. 
In 2004, Nann et al. prepared single-dot@SiO2  nanoparticles 
by  the  Stöber  method.70   Yang  and  his  co-workers  prepared 
similar CdTe@SiO2  nanoparticles by the reverse microemulsion 
approach.69   These  single-dot@SiO2   nanoparticles  show  a  low 
75  fluorescence QY (< 10%), however. Later on, the fluorescence 
QY of CdTe@SiO2  nanoparticles was improved to 47%. In 
comparison with incubated CdTe QDs (83%), nearly 40% of the 
fluorescence was still lost during silica coating.71  The formation 
of single-dot@SiO2 nanoparticles is attributed to the electrostatic 
80  repulsion between QDs and silica intermediates. 
In order to improve the fluorescence QY and the number of 
QDs in each SiO2 nanoparticle, we successfully prepared 





















Figure 5. (a) Size-dependence of SiO2@CdTe@SiO2 
nanoparticles on tetraethyl orthosilicate (TEOS) volume; (b- 
d)  size-dependence  of  cytotoxicity  and  cell  uptake. 
Reproduced from Ref. 74. 
 
novel strategy (Figure 4).72  We started from the synthesis of the 
thiol-capped  SiO2   core.  The  surface  thiol  groups  can  tightly 
anchor CdTe QDs on the surface of SiO2 nanospheres. Then, a 
silica  layer  was  coated  on  the  SiO2@CdTe  to  form  SQS 
5  nanoparticles. During the silica coating, it is important to add an 
appropriate amount of 3-mercaptopropyl-trimethoxysilane (MPS) 
for pre-coating in order to get highly fluorescent sandwich-like 
nanoparticles.  Compared  with  other  QDs@SiO2   nanoparticles, 
our SQS nanopaticles show the highest fluorescence QY ever 
10  reported (up to 61%). They also show higher stability and lower 
toxicity in comparison with SiO2@CdTe nanoparticles. 
During the modification of QDs, the overall particle size has to 
be strictly controlled because it can dramatically influence the 
nanoparticle  biological  behaviour,  such  as  cell  internalization, 
15  tumour targeting and penetration, in vivo systemic and lymphatic 
biodistribution, metabolism, and clearance. Nanoparticles with a 
size of 20-60 nm have shown distinct biodistribution, tumour 
penetration, and cellular tracking properties.73  Therefore, we 
prepared a series of SQS nanopaticles with sizes in the range of 
20  39 nm to 76 nm by controlling the reaction parameters, including 
the amount and the type of silica precursor, the ratio of silica 
Figure 6. (a) Structure of a multifunctional QD probe; (b) 
C4-2 cells labelled with multifunctional QDs; (c) In vivo 
targeted imaging using multifunctional QDs; (d) multicolour 
capability of QD imaging in live mouse.  Reproduced from 
Ref. 76. 
QDs were internalized into the cells in the presence of transferrin 
40  due to the occurrence of receptor-mediated endocytosis. 
Motivated by the above pioneering research, extensive 
nonspecific and targeted bio-labelling and imaging have been 
carried out at different levels, ranging from in vitro to in vivo 
models.10-12   Nonspecific  cellular  labelling  involves  the  use  of 
45 hydrophobic  and  electrostatic  interactions  between  surface- 
capping   molecules   of   QDs   and   biomolecules   in   the   cell 
membrane. Thus, their surface ligand properties and the cell type 
largely determine the nonspecific adsorption and uptake of QDs. 
In most cases, such nonspecific adsorption is unwanted, as this 
50 reduces the selectivity and targeting efficiency. In order to 
overcome nonspecific adsorption, PEG and its derivatives have 
been used to modify the QD surface, as they can effectively 
minimize and prevent the nonspecific interactions of QDs with 
biomolecules, cells, and tissues. 
55  Similar to the in vitro nonspecific adsorption of cells, non- 
targeted   QDs   can   accumulate   within   tumours   through   the 
enhanced permeability and retention (EPR) effect. Such passive 
targeting is attributed to the leakiness of the tumour vasculature 
and the poor lymphatic drainage, which enables QDs or other 
75
 
precursor to ammonia, and the ratio of H2O to surfactant.
74 These 60  nanoparticles to accumulate in tumours. The EPR effect could 
SQS  nanoparticles  exhibited  strong  size  dependence  of  their 
stability, toxicity, and cellular uptake (Figure 5). Our findings 
25 highlight the importance of controlling particle size and shell 
thickness during the preparation of fluorescent QDs@SiO2  core- 
shell nanoparticles. 
 
2.3 Fluorescence imaging of QDs 
 
The earliest bioapplications of fluorescent QDs were reported in 
30  1998.64, 67 Bruchez et al. coated core-shell CdSe@CdS QDs with 
a thin layer of silica and then conjugated them with biotin.67 The 
biotinylated QDs were successfully applied to label 3T3 mouse 
fibroblast cells. Chan et al. used small molecule TGA to transfer 
hydrophobic  CdSe@ZnS  QDs  into  water  solution,  and  then 
lead to more than 50 times as great nanoparticle accumulation in 
tumours compared with healthy tissues. It is difficult, however, to 
maximize nanoparticle accumulation through the EPR effect, as 
this effect varies from tumour to tumour, and strongly depends on 
65  the particle size and the surface charge.75  In addition, the EPR 
effect is not commonly observed in some types of cancers such as 
gastric and pancreatic cancers. 
An  alternative  approach  is  active  targeting,  which  can  be 
achieved  by conjugating QDs  with  targeting  moieties  such  as 
70  small molecules (e.g. folic acid and hyaluronic acid), peptides 
(e.g. arginine-glycine-aspartic acid (RGD)), and proteins (e.g. 
antibodies, antibody fragments, transferrin, etc.).12  In 2004, Gao 
and  colleagues  reported  a  landmark  work  on  in  vivo  cancer 
76
 
35  conjugated   them   with   transferrin   proteins.64     The   authors targeting   with   QDs   (Figure   6). They   first   encapsulated 
incubated  TGA-modified  QDs  and  transferrin-QD  conjugates 
with HeLa cells, respectively, and found that no QDs could be 
observed inside the cell in the absence of transferrin. In contrast, 
75  hydrophobic CdSe@ZnS core-shell QDs with an ABC triblock 
copolymer (i.e. polybutylacrylate-polyethylacrylate- 
polymethacrylic    acid)    by    using    hydrophobic-hydrophobic 
 
 
interactions between the capping ligands of QDs and the 
hydrophobic segments of the block copolymer. Then, they 
conjugated tumour-targeting ligands and drug-delivery 
functionalities  with  the  polymethacrylic  acid  segment.  The  in 
5  vivo  study  showed  that  these  QD  probes  accumulated  at  the 
tumour site through the EPR effect, and the specific antibody- 
antigen interactions. It is worth mentioning that passive targeting 
is much slower and less efficient than active targeting. 
Although targeted nanoparticles hold much promise, and the 
10  concept was introduced more than 30 years ago, none of them has 
been clinically approved.75  One possible reason is the huge gap 
between cost and benefit. Compared with expensive antibodies 
and other targeting ligands, cost-effective small molecules such 
as folic acid have been adopted. Folic acid and folate conjugates 
15  can be specifically recognized by the folate receptor (FR), which 
is a glycosylphosphatidylinositol-anchored protein. The alpha 
isoform of FR (FR-α) is found to be overexpressed in many 
epithelial cancers, but not highly expressed in normal tissues 
except for the kidney. Since the affinity of FR to folic acid and 
20  folate conjugates is relatively high (Kd ≈ 100 pM), FR-α has been 
extensively investigated for tumour targeting,77 including many 
studies focusing on QDs. For example, folic acid was conjugated 
to  PEG  and  subsequently  deposited  onto  N-acetyl-L-cysteine 
(NAC)-stabilised  CdTeS  QDs,  which  was  demonstrated  to  be 
25  able to target tumours in mouse models.78 Another small targeting 
molecule   is   hyaluronic   acid,   which   is   widely   distributed 
throughout connective, epithelial, and neural tissues. Hyaluronic 
acid, associated with tumour angiogenesis and progression,79 has 
been  conjugated  to  QDs  for  tumour  targeting,  as  it     can 
30 specifically  bind  with  CD44,  a  cell-surface  glycoprotein 
overexpressed in many tumour types. Therefore their conjugates 
have not only cancer targeting characteristics, but also the 
capability for imaging lymphatic vessels.80 
In addition to the high cost, the low targeting efficacy and the 
35  unclear mechanism could  also limit their clinical applications. 
This is because not all cancer cell types overexpress the same 
unique  receptors,  and  the  overexpressed  receptors  are  often 
present on normal cells.75  Moreover, the density of the targeted 
receptors on tumour cells could be another factor influencing the 
40  targeting efficacy. For II-VI QDs, the biggest challenge for their 
clinical applications is their potential toxicity, as discussed in the 
following section. 
 
2.4 QD toxicity 
 
Most II-VI QDs consist of toxic elements such as cadmium, 
45  lead, mercury, etc. Their toxicity has always been of concern and 
could limit the diversity of their applications, such as in solar 
cells, light-emitting diodes, flat-screen televisions, and 
biomarkers.81  The bio-toxicity depends on multiple factors,82 
which can be mainly classified into two groups: (1) the inherent 
50 properties of QDs, including QD size, charge, composition, 
concentration, and outer-layer coating bioactivity (capping 
material, functional groups); (2) environmental factors such as 
oxidation,  photolysis,  and  mechanical  effects.  A  number  of 
studies show that appropriate surface modification, modulating 
55  the surface charge, and controlling the QD dosage can effectively 
reduce QD cytotoxicity. Previously, we demonstrated that coating 
QDs with silica shells can improve their stability and reduce the 
 
toxicity (Figure 5).74 Some research has shown that the release of 
Cd2+  and the oxidation products of anions are responsible for 
60  their bio-toxicity.66 The QDs themselves (i.e. non-degraded QDs) 
are not acutely toxic, and they can be retained in the body for two 
years and remain fluorescent. 
In 2007, Choi and co-workers studied the renal clearance of 
QDs.83   They chose  cationic,  anionic, zwitterionic,  and  neutral 
65  molecules to modify CdSe@ZnS core-shell QDs and tested their 
binding with serum proteins. They found that the QD surface 
charge has a profound effect on the adsorption of serum proteins 
and the hydrodynamic diameter. Cationic or anionic charge led to 
the hydrodynamic size increasing from around 5 nm to over 15 
70  nm after incubation with serum. Neutral (PEGylated) QDs did not 
aggregate, but had a large size. Zwitterionic coatings prevented 
serum  protein  adsorption  and  produced  the  smallest 
hydrodynamic size. The biodistribution results show that a final 
hydrodynamic diameter < 5.5 nm resulted in rapid and efficient 
75  urinary excretion and elimination of QDs. In their later report, the 
authors conjugated small targeting molecules on the surface of 
zwitterionic coatings of QDs.84  These targeted probes were also 
cleared by the kidneys when their hydrodynamic size was smaller 
than 5.5 nm, which sets an upper limit of 5–10 ligands per QD for 
80 renal   clearance.   The   animal   models   demonstrated   their 
performance for in vivo targeted imaging and renal clearance 
within 4 h post-injection. 
Recently, Ye et al. injected phospholipid micelle-encapsulated 
CdSe/CdS/ZnS  QDs  into  rhesus  macaques,  and  tracked  the 
85  relevant markers in the next 90 days.85 Their results demonstrated 
that the acute toxicity of these QDs in vivo is minimal. 
Accumulation of an initial dose of Cd was found in the liver, 
spleen, and kidneys, however, even after 90 days, indicating slow 
breakdown and clearance of the QDs. Although QDs have not 
90  shown acute or short-term toxicity, comprehensive assessments 
of their long-term bio-toxicity are needed to confirm the ultimate 
fate of these heavy metals and the impact of their persistence in 
primates for potential clinical use. 
 
 
95  3 Fluorescent metal nanoclusters 
 
Since QDs have potential toxicity and long in vivo retention time, 
many efforts have been made to develop alternatives to them. An 
alternative is fluorescent metal nanoclusters, which have attracted 
considerable attention during the past several  years. It is well 
100  known that large nanoparticles of metals such as Au, Ag, and Cu 
possess the face-centred cubic (fcc) structure and the surface 
plasmon resonance (SPR) property.86 Their SPR absorption is due 
to the collective oscillation of electrons on the surfaces, and it is 
strongly dependent on the particle size. When that size is smaller 
105  than the electron mean path (e.g. 20 nm for Au nanoparticles), the 
conducting electrons in the ground states and excited states are 
confined.86 The large metal nanoparticles have very low 
fluorescence emission. Very interestingly, when their size is 
further reduced below 2 nm, the ultra-small nanoclusters possess 
110  different crystal structures and exhibit strong photoluminescence 
while their unique SPR property disappears. 
Nanoclusters    bridge    the    gap    between    molecules    and 
nanoparticles, and could simultaneously display the properties of 
both molecules and nanoparticles. Their novel optical, electronic, 
 
 
and catalytic activities make them very useful in ultrasensitive 
detection, biolabelling, bioimaging, and catalysis.87-90 The big 
challenge, however, is how to controllably synthesize metal 
nanoclusters with defined size, composition, crystal structure, and 
5  surface properties.88, 91 
 
3.1 Synthesis of fluorescent metal nanoclusters 
 
Compared   with   large  nanoparticles,   metal  nanoclusters  are 
difficult to synthesize and functionalize because they only consist 
of a few to tens of metal atoms. They are very sensitive to slight 
10 variation of the environment, such as solution pH, ion strength, 
solvents, oxygen, temperature etc. They have very high surface- 
area-to-volume ratios and tend to aggregate into large particles. In 
general, fluorescent metal nanoclusters can be prepared by 
reduction of metal precursors or etching of large nanoparticles in 
15  the presence of strong stabilizers such as small thiol-molecules, 
polymers, and biomolecules. 
Reduction of metal precursors such as salts and complexes is a 
straightforward way to produce fluorescent metal nanoclusters. 
Au   nanoclusters   are   usually   chosen   as   representative   for 
20 investigation   due   to   their   high   chemical   stability,   easy 
preparation, and biocompatibility. The first observation of Au 
photoluminescence  from  its  ingots,  single-crystal  slices,  and 
films, with a QY of 10-10, was reported by Mooradian in 1969.92 
The  extremely  low  QY  did  not  attract  any  attention  until 
25 Wilcoxon  et  al.  observed  fluorescence  from  colloidal  Au 
nanoparticles with a QY of 10-5 – 10-4.93 The authors prepared 
colloidal  Au  nanoparticles  through  reduction  of  HAuCl4   by 
citrate in water, or by metallic sodium dispersion or lithium 
trisamylborohydride  in  inverse  micelles,  and  then  used  liquid 
30  chromatography  to  fractionate  the  resultant  Au  nanoparticles. 
They found that only nanoparticles smaller than 5.0 nm showed a 
blue fluorescence at 440 nm under an excitation of 230 nm. Their 
results suggest that ultra-small nanoclusters could exhibit strong 
fluorescence. 
35  A breakthrough in preparing fluorescent Au nanoclusters was 
achieved by Zheng and co-workers.94-96 They synthesized a series 
of Au5, Au8, Au13, Au23, and Au31 nanoclusters using 
poly(amidoamine) (PAMAM) dendrimers as stabilizers. By 
adjusting the molar ratio between Au3+ and PAMAM from 1:1 to 
40  1:15, they tuned the emission of these Au nanoclusters from the 
ultraviolet (UV) to the near infrared (NIR) range with a QY from 
10% to 70%. The latter experiments, however, proved that 
PAMAM dendrimers made a contribution to the solution 
fluorescence.  The  authors  also  used  dendrimers  as  ligands  to 
45  prepare   fluorescent   Ag   nanoclusters.89,    97     In   addition   to 
dendrimers, some other polymers such as multiarm star 
polyglycerol-block-poly(acrylic acid) and DHLA functionalized 
PEG were used to stabilize metal nanoclusters. 98, 99 
Recently, we used multidentate thioether-terminated 
50  poly(methacrylic acid) (PTMP-PMAA) (Figure 7(a)) as ligand to 
successfully prepare water-soluble fluorescent Au nanoclusters 
through reduction of HAuCl4  with NaBH4.
100  Due to the strong 
steric effect, this polymer ligand has also been used to prepare 
ultra-small    magnetic    iron    oxide    nanoparticles.101-104      By 
55  controlling the polymer concentration and molecular weight, we 
obtained a series of Au nanoclusters with emissions between 540 
– 800 nm and QYs of 2.6 – 4.8%. In contrast to dendrimers, our 
Figure 7. Schematic diagram of preparation of (a) polymer 
ligand   PTMP-PMAA;   (b)   photoreductive   synthesis   of 
fluorescent Cu, Ag, and Au nanoclusters; (c) TEM image of 
Au nanoclusters. Reproduced from Ref. 100 and Ref. 105. 
 
polymer  ligands  did  not show fluorescence,  and  the  observed 
fluorescence  was  only  caused  by  the  Au  nanoclusters.  The 
60  different  emissions  of  Au  nanoclusters  are  attributed  to  their 
different sizes. On the basis of this research, we prepared 
fluorescent Au, Ag, and Cu nanoclusters using photoreduction 
rather than chemical reduction (Figure 7(b)).105 Compared with 
conventional  chemical  reduction,  photoreduction  is  clean  and 
65 non-toxic as this method avoids the use of additional reducing 
agents. The QYs of the resultant Au, Ag, and Cu nanoclusters 
were 5.3%, 6.8%, and 2.2%, respectively. Using the 
photoreduction method, Shang et al. also prepared very highly 
fluorescent  Ag  nanoclusters  (18.6%  QY)  in  the  presence  of 
70  poly(methacrylic acid) (PMAA).106 
Compared with PMAA, our polymer ligands have a stronger 
steric hindrance effect. Figure 7(c) presents a typical transmission 
electron microscope (TEM) image of Au nanoclusters stabilized 
with PTMP-PMAA, clearly showing their ultra-small size (< 1.0 
75  nm). In order to further investigate the polymer hindrance effect, 
we   designed   three   types   of   tridentate   thioether-terminated 
 
 
polymer ligands,107 i.e. poly(methyl methacrylate) (PTMP- 
PMMA), poly(n-butyl methacrylate) (PTMP-PBMA), and poly(t- 
butyl methacrylate) (PTMP-PtBMA), which were used to 
synthesize   fluorescent   Au   nanoclusters   through   the   facile 
5  photoreduction method. The resultant Au nanoclusters exhibited 
blue fluorescence instead of red fluorescence due to their small 
particle  size.  Their  QYs  were  found  to  be 3.8%, 14.3%,  and 
20.1%, respectively, which increases with increasing polymer 
steric hindrance, i.e. PTMP-PMMA < PTMP-PBMA < PTMP- 
10  PtBMA. 
In addition to polymer ligands, small thiol molecules such as 
glutathione, tiopronin, MPA, DHLA, phenylethylthiolate, and 
thiolate  α-cyclodextrin  were  also  used  to  prepare  fluorescent 
metal  nanoclusters.87,  108,  109   For example,  Luo  et  al.  used  L- 
15  glutathione as ligands to prepare Au(0)@Au(I)-thiolate core-shell 
nanoclusters with a QY of 15%.109 They proposed that strong 
luminescence emission is attributed to aggregation-induced 
emission of Au(I)-thiolate complexes. The QYs of metal 
nanoclusters stabilized by small molecules are similar to those 
20  nanoclusters stabilized with polymer. 
In order to improve the biocompatibility of fluorescent metal 
nanoclusters, several groups used biomolecules such as 
oligonucleotides, peptides, and proteins as stabilizers during 
preparation.110-113     For   example,   the   Dickson   group   took 
25  advantage of the strong affinity of Ag+  to cytosine bases from 
single-stranded DNA, and prepared very small Ag nanoclusters 
using DNA as stabilizer.110  In their later report, they used DNA 
microarrays for high-throughput analysis of 12-mer strands to 
identify optimized sequences for Ag encapsulation, and produced 
30  five distinct Ag emitters with QYs in the range of 16 – 34%.111 
Compared with single-stranded DNA, proteins have abundant 
binding sites and offer better protection to metal nanoclusters. 
Xie et al. prepared Au25  nanoclusters with a QY of 6.0% using 
bovine  serum  albumin  (BSA)  as  the  stabilizer  and  reducing 
35  agent.112   The  reduction  process  was  induced  by  adjusting  the 
solution pH. 
Similar to the QDs produced in living organisms, fluorescent 
metal nanoclusters can also be formed in-situ in cells. For 
example,  Wang  and  co-workers  found  that  fluorescent  Au 
40  nanoclusters were spontaneously biosynthesized by cancer cells 
(human hepatocarcinoma cell line HepG2 and leukaemia cell line 
562) rather than normal cells such as human embryo liver cells 























Figure 8. (A-B) Solutions of Ag7,8  and alloyed Ag7Au6 
nanoclusters;  (C-D) their absorption  and emission  spectra; 
(E) alloyed Ag7Au6  nanoclusters in solution and in the solid 
state  under  visible  and  UV  light;  (F)  comparison  of  the 
PAGE  of  Ag7,8   and  alloyed  Ag7Au6   nanoclusters. 
Reproduced from Ref. 117. 
stabilized Ag nanoparticles and then added them into an organic 
60 solvent  (e.g.  toluene,  carbon  tetrachloride,  diethyl  ether) 
containing excess MSA under magnetic stirring. A mixture of 
Ag8 and Ag7 nanoclusters with red and blue-green fluorescence 
was obtained. The QYs of the Ag8 nanoclusters at room 
temperature  and  273  K  were  calculated  to  be  0.3%  and  9%, 
65  respectively.  The  authors  used  a  similar  approach  to  obtain 
alloyed Ag7Au6  nanoclusters (3.5% QY) by adding HAuCl4 
solution into the as-etched Ag nanocluster solution (Figure 8).117 
In addition to small molecules, multivalent polymers can also 
be   used   as   etching   agents.   Duan   et   al.   used   multivalent 
70  polyethylenimine (PEI) to etch 8  nm Au nanoparticles, which 
were prepared by a two-phase approach and stabilized with 
dodecylamine.  The  resultant  cluster  solution  surprisingly 
appeared to be in an oxidized electronic state with an emission at 
505 nm. The emission was blue shifted to 445 nm with a QY of 
75  10  - 20% after reduction with NaBH4.
118
 
Similar to organic ligands, metal precursors can also induce 
the etching process. For example, Lin and co-workers extracted 
solution.114  Au nanoclusters were formed by reduction of Au- HAuCl4 from aqueous solution into 
45  precursor inside the cell cytoplasm and concentrated around their 
nucleoli. The selective formation of fluorescent Au nanoclusters 
by cancer cells can be exploited for in vivo self-bio-imaging of 
tumours. 
 
Etching of large metal nanoparticles is an alternative approach to 
50  prepare fluorescent metal nanoclusters. The etching process can 
be performed by adding strong ligands or precursors into the 
nanoparticle solution. For example, Muhammed et al. synthesized 
didodecyldimethylammonium bromide (DDAB) toluene solution, 
80  and then added the mixture into 5.6 nm Au solution to result in 
3.2  nm  particles.119   After  replaced  DDAB  with  dihydrolipoic 
acid, these Au nanoparticles were further decreased to 1.6 nm and 
showed a red emission around 700 nm. Their fluorescence QY 
was 3.4% in methanol and 1.8% in water (pH = 9). Recently, 
85  Yuan  et  al.  developed  a  general  etching  approach  to  prepare 
fluorescent Au, Ag, Cu and Pt nanoclusters with a QY of 5.4%, 
120
 
fluorescent Au nanoclusters from MSA-stabilized Au 
6.5%,   3.5%   and   4.6%,   respectively. They   started   with 
nanoparticles by etching with excess glutathione.115  The etching 
55 process  is  pH-dependent  and  the  obtained  Au8   and  Au25 
nanoclusters have a QY of 0.015% and 0.19%, respectively. They 
also developed an interfacial  etching process to prepare 
fluorescent   Ag   nanoclusters.116    First,   they   prepared   MSA- 
glutathione-stabilized  metal  nanoparticles,  and  then  transferred 
the metal nanoparticles into an organic phase by taking advantage 
90 of  the  electrostatic  interactions  between  negatively  charged 
glutathione (carboxyl group) and positively charged 
cetyltrimethylammonium bromide (CTAB). The beauty of this 
 
 
approach is that the resultant fluorescent metal nanoclusters can 
be shuttled back to the aqueous phase using hydrophobic- 
hydrophobic interactions upon addition of hydrophobic salts (e.g. 
tetramethylammonium decanoate) in chloroform. 
5  Besides these methods, microwaves and ultrasound were also 
used to assist the synthesis of fluorescent metal nanoclusters in 
recent years.121, 122 For example, Xu and Suslick adopted 
sonochemistry to prepare fluorescent Ag nanoclusters with a QY 
of 11% in the presence of PMAA.121  Shang et al. synthesized 
10 fluorescent Au nanoclusters (2.9% QY) via a rapid microwave 
assisted method.122 In all syntheses, ligands play a crucial role in 
obtaining these ultra-small fluorescent metal nanoclusters. Their 
ability to donate electrons drastically influences the fluorescence 
intensity, i.e. the stronger the electron donating capability is, the 
15  higher the fluorescence intensity will be. 123 
 
3.2  Characterization  and  modification  of  fluorescent  metal 
nanoclusters 
 
Metal nanoclusters can be characterized by the techniques applied 









Figure 9. (a) Kohn-Sham orbital energy level diagram for a model 
compound Au25(SH)18; (b) Solid-state model for the origin of the 
two luminescence bands in (d); (c) theoretical absorption spectrum 
of Au (SH) ; (d) two luminescence peaks observed in Au (SG) 25 18 28 16 
20  nanoparticles,  metal  nanoclusters  have  a  smaller  size  and  a 
“narrower” size distribution, so that size-selective precipitation is 
not suitable for their separation. They are usually fractionated by 
chromatography   and   electrophoresis   techniques,   which   are 
usually applied to molecules. These separation methods include 
25  high-performance liquid chromatography (HPLC), size exclusion 
chromatography (SEC), ion exchange chromatography (IEC), 
capillary electrophoresis, and polyacrylamide gel electrophoresis 
(PAGE).  It  is  still  very  challenging  to  obtain  monodisperse 
clusters. Reproduced from Ref. 131 and Ref. 132. 
The ultra-small size (limited atomic numbers) of metal 
nanoclusters makes it possible to predict their crystal structures 
through precise theoretical simulation. For example, Xiang et al. 
60 developed a new genetic algorithm approach to search for the 
global lowest-energy structures of DMSA-stabilized Ag 
nanoclusters.129 In combination with density functional theory 
(DFT), their genetic algorithm simulations show that the ground 
state of [Ag (DMSA) ]−  has eight instead of four Ag−S bonds, 
nanoclusters using these approaches. For example, Tsunoyama et 
7 4 
65  with  a  much  lower  energy  than  the  structure  based  on  the 
30  al. separated Au:SCx  nanoclusters into different fractions using [Ag (SR) ]− cluster with a quasi-two-dimensional Ag core. Their 
gel permeation chromatography (GPC),124 and then characterized 
7 4 7 
 
them with laser-desorption ionization (LDI) mass spectroscopy. 
The results show that each fraction had a wide distribution of Au 
atoms although they were well separated with high resolution in 
35 the   GPC   spectrum.   Negishi   and   co-workers   synthesized 
glutathione-protected Au nanoclusters and then fractionated them 
into 9 fractions, with the number of Au atoms ranging from 10 to 
39   by   PAGE   analysis.125     Among   their   Au   nanoclusters, 
Au25(SG)18 is the most stable one. 
40  The size of fractionated metal clusters can be characterized by 
TEM, and their molecular weight can be measured by mass 
spectroscopy. In principle, their crystal structures could be 
determined by X-ray diffraction (XRD). Metal nanoclusters are 
less ordered, however, and their powder XRD patterns are broad. 
simulated X-ray diffraction pattern of the [Ag7(DMSA)4]
− cluster 
is in good agreement with the experimental results. 
The optical properties of fluorescent metal nanoclusters can be 
70 characterized   with   UV-visible   (UV-Vis)   absorption   and 
photoluminescence   spectroscopy.   As   mentioned   previously, 
metal nanoclusters have no SPR absorption, but they show 
molecular-like electronic transitions due to the quasi-continuous 
energy band structure and quantum confinement effects. Bakr et 
75 al. synthesized Ag nanoclusters through the reduction of Ag- 
precursor in the presence of 4-fluorothiophenol,130  and 
investigated the evolution of their absorption from multiple bands 
into  a  single  SPR  band  by  heating  the  original  nanocluster 
solution  at  90  ˚C  for  different  periods  of  time.  Their  results 
80  demonstrate the size dependence in UV-Vis absorptions of metal 
45  In  comparison  with  metal  complexes  with  defined  molecular 
structure, it is very difficult to obtain single crystal clusters for 
structural characterization. So far, most structural investigations 
of metal nanoclusters are focused on “large” Au nanoclusters.91, 
108, 126-128  For example, Jadzinsky et al. determined the structure 
50  of a Au102(p-mercaptobenzoic acid)44  single crystal and found a 
core-shell structure,127  in the which the Au49  core is surrounded 
by two groups of Au atoms. Qian and co-workers characterized 
the crystal structure of Au25(SR)18  and Au38(SR)24  nanoclusters, 
and found a similar core-shell structure.91  An Au25(SR)18  cluster 
55  consists of an icosahedral Au13 core and exterior 12 Au atoms in 
the form of six –RS–Au–RS–Au–RS– motifs.91, 108 
nanoclusters. 
In order to demonstrate the origin of multiband absorption, 
Zhu and co-workers chose the Au25(SR)18 cluster as a model and 
simulated  their absorption by performing time-dependent DFT 
85  calculations.131   Figure  9(a)  shows  the  Kohn-Sham  molecular 
orbitals, energies, and atomic orbital contributions in the cluster. 
The highest occupied molecular orbital (HOMO) and the lowest 
three lowest unoccupied molecular orbitals (LUMOs) are mainly 
composed  of  6sp  atomic  orbitals  of  Au,  and  these  orbitals 
90 constitute the sp-band. The HOMO-1 to HOMO-5 orbitals are 
constructed from the 5d atomic orbitals of Au and form the d- 
band. In addition, the s 3p orbitals make contributions to both sets 
of  HOMO  and  LUMO  orbitals.  The  multiband  absorption  of 
 
 
metal nanoclusters suggests their multiple emission peaks and 
broad fluorescence spectra (Figure 9(b)). Figure 9(c) shows the 
simulated absorption spectrum. The multiple absorptions are 
attributed to the intraband (sp) HOMO → LUMO transition, the 
5  interband transition (d → sp), or mixed sp → sp intraband and d 
→ sp interband transitions.131 Figure 9(d) shows two fluorescence 
bands with the maxima at around 1.5 and 1.15 eV observed in 
Au28(GSH)16  nanoclusters by Link et al.
132  These two bands are 
separated from a broad luminescence in the range of 2.0 – 0.8 eV, 
10  and are ascribed to the radiative interband recombination between 
the sp and d bands, and intraband transitions (sp bands) between 
the HOMO and LUMO. 
Despite  the  good  agreement  between  simulated  data  and 
experimental observations, the origin of metal fluorescence is not 
15 completely   understood.   Most   reported   atomically   precise 
Aun(SR)m nanoclusters show very weak luminescence. Recently, 
Yu and co-workers identified that Au22(SR)18 has two RS-[Au- 
SR]3   and  two  RS-[Au-SR]4   motifs  that  are  interlocked  and 
capped on a prolate Au8 core.133  These Au22(SR)18 nanoclusters 
20  exhibited an emission at ∼665 nm with a QY of ∼8%. Their
 
results   show   that   the   luminescence   of   these   core-shell 
nanoclusters was generated by the aggregation-induced emission 
of Au(I)-thiolate complexes on the nanocluster surface. 
The fluorescence of metal nanoclusters is very sensitive to the 
25  cluster size, surface ligands, solvents, etc., so it is thus necessary 
to modify them in order to maintain their bright fluorescence in 
addition to improving their stability and biocompatibility. There 
are few reports, however, on the post-modification of fluorescent 
metal nanoclusters in comparison with large nanoparticles, due to 
30  their tiny size and sensitivity to external conditions. Lin and co- 
workers prepared DHLA-protected fluorescent Au nanoclusters 
by etching large nanoparticles and replacing surface ligands.119 
They took advantage of carboxylic acid groups from DHLA to 
conjugate PEG–NH2  or biotin-PEG–NH2  with Au nanoclusters. 
35  The  gel  electrophoresis  and  the  cell  labelling  indicate  the 
successful conjugation. Samanta et al. prepared fluorescent Au 
nanoclusters using a novel quaternary ammonium as the ligand, 
and then coated them with silica.134  Similar to fluorescent QDs, 
surface modification can lead to the fluorescence quenching of 
40 metal nanoclusters. It is still a great challenge to obtain robust 
fluorescent metal nanoclusters through surface modification. 
 
3.3 Application of fluorescent metal nanoclusters in bioimaging 
 
Similar to other fluorophores, fluorescent metal nanoclusters have 
also been tested for in vitro and in vivo bioimaging. In the early 
45  reports, Zheng et al. prepared fluorescent Au, Ag nanoclusters in 
the presence of dendrimers, DNA, and proteins, and used them as 



































Figure 10. Comparison of cell labeling by using fluorescent 
Au nanoclusters and CdTe QDs. Reproduced from Ref. 100. 
 
labelling suspended and adherent hematopoietic relatively normal 
cord blood mononuclear (CBMC) cells and cancer K562 cells 
60  (Figure 10).100  The results show that the cancer cells took up 
more Au nanoclusters than the normal cells, even though they 
were from the same hematopoietic system. There was no 
difference, however, in the uptake of CdTe QDs between the two 
kinds of cells. The selective uptake of Au nanoclusters by cancer 
65  cells   could   be   attributed   to   the   unique   properties   of   Au 
nanoclusters or the nature of the cells. In addition, CdTe QDs 
destroyed the nuclei of some cells. We also compared the 
cytotoxicity of Au nanoclusters with that of CdTe QDs through 
MTT and apoptosis assay. The results show that our fluorescent 
70  Au nanoclusters had lower toxicity than QDs, and did not induce 
acute toxicity. These advantages make them very attractive in 
selective bio-labelling of cancer cells. Retnakumari et al. 
conjugated folic acid with BSA-stabilized Au nanoclusters and 
136
 
Ag nanoclusters in the presence of thioflavin T with remarkable 
fluorescent properties,135  and then used them to label amyloid 
then  used  them  for  targeted  imaging. 
75  cancer detection was demonstrated on FR 
The  receptor-targeted 
+ve  oral squamous cell 
50  fibrils produced from recombinant mammalian prion proteins and 
non-prion proteins. The labelled amyloid fibrils exhibited a time- 
dependent increase in fluorescence with no photobleaching after 
carcinoma (KB) and breast adenocarcinoma MCF-7 cells, where 
the FA-conjugated Au25 clusters were found to be internalized in 
significantly  higher  concentrations  compared  to  the  negative 
136
 
24-h illumination, while those stained with thioflavin T showed a 
control  cell  lines. Apart  from  routine  utilization  of  cell 
rapid decay in fluorescence. Their results demonstrate the higher 
55  stability of Ag nanoclusters than that of organic fluorophore. 
Recently, we prepared fluorescent Au nanoclusters stabilized 
with PTMP-PMAA, and then compared them with CdTe QDs in 
80  labelling,   fluorescent   metal   nanoclusters   can   be   used   as 
intracellular sensors. For example, Shang and co-workers 
demonstrated the use of Au nanoclusters for intracelluar 
thermometry by taking advantage of the temperature sensitivity 




















Figure 11. FLIM images of HeLa cells with internalized Au 
nanoclusters at four different temperatures. Reproduced from 
Ref. 15. 
 
11).15 Using fluorescence lifetime imaging microscopy (FLIM), 
they observed the considerable variation of fluorescence lifetime 
of nanoclusters internalized in HeLa cells with the temperature 
increasing from 15 to 45 ˚C. 
5  In addition to the above in vitro cell labelling and imaging, Wu 
et al. investigated in vivo imaging through the tail vein 
administration of near infrared (NIR) fluorescent Au nanoclusters 
in live mice,137 and found that the uptake of NIR Au nanoclusters 
by   the   reticuloendothelial   system   was   relatively   low   in 
10 comparison with other nanoparticles due to their ultra-small 
hydrodynamic size (~2.7 nm). They then used MDA-MB-453 and 
xenografted HeLa tumour cells as models to do in vivo and ex 
vivo imaging studies, and found that the ultra-small Au 
nanoclusters were highly accumulated in the tumour areas due to 
15  the enhanced permeability and retention (EPR) effect.137 
Zhou  and  co-workers  studied  the  renal  clearance  of  2  nm 
glutathione  (GSH)-coated  fluorescent  Au  nanoclusters  (Figure 
12),138 and found that only ~4% of the particles were accumulated 
in the liver, while more than 50% of the particles were found in 
20  urine within 24 h after intravenous injection, which is comparable 
to the QDs with the best renal clearance efficiency.83  They also 
used computed tomography (CT) to visualize real time 
accumulation of luminescent GS-AuNPs in the bladder, and 
demonstrated  that  fluorescent  Au  nanoclusters  can  serve  as 
25 contrast agents for CT imaging (Figure 12). Recently, they 
compared GSH-coated fluorescent Au nanoclusters (2.5 nm) with 
small dye molecules IRDye 800CW,139  and found that they both 
have similar physiological stability and renal clearance, but Au 
nanoclusters exhibited a much longer tumour retention time and 
Figure 12. (a) Biodistibution of 2-nm GS-Au nanoclusters. 
The inset shows CT images of a live mouse before and 30 
min after injection of Au nanoclusters; (b-d) comparison of 
biodistribution of GS-Au nanoclusters and IRDye 800CW. 
Reproduced from Ref. 138 and Ref. 139. 
 
that an injection of insulin-Au nanoclusters into the rats tended to 
reduce the blood glucose in a similar way to commercial insulin. 
Fluorescent insulin-Au nanoclusters can also be used as contrast 
agents for CT imaging.113  These studies indicate that ultra-small 
45 fluorescent Au nanoclusters could simultaneously serve as very 
promising contrast agents for in vivo fluorescence imaging and 
CT imaging. 
In  summary,  fluorescent  metal  nanoclusters  as  emerging 
fluorophores have attracted considerable attention due to their 
50  tuneable emissions, ultra-small size, fast renal clearance, and low 
toxicity. There are a few obstacles to be overcome, however, 
including (i) low fluorescence QY, which is usually about ~10% 
and less than that of QDs and many organic dyes; (ii) 
polydispersity  in  size  and  components,  which  makes  it  very 
55 difficult  to  fundamentally  study  their  novel  properties  and 
mechanisms;   (iii)   difficulty   in   modifying   their   surface   to 
introduce other functions due to their tiny size and lower stability; 
(iv) complicated interactions with biological environments. 
 
 
60  4 Fluorescent carbon nanomaterials 
 
4.1 Fluorescent carbon dots 
 
Fluorescent carbon dots are also used as alternatives to QDs for 
bioimaging,17, 140 because they not only exhibit several favourable 
attributes of traditional semiconductor-based QDs (namely, size- 
65 and      wavelength-dependent      emission,      resistance      to 
photobleaching, ease of bioconjugation), but also show chemical 
inertness, low toxicity, and biocompatibility. Fluorescent carbon 
dots were accidently discovered in 2004 during the purification of 
single-wall carbon nanotubes (SWCNTs) fabricated by the arc- 
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30  faster normal tissue clearance (Figure 12). These merits enabled 70  discharge approach. Two new classes of nanomaterials were 
the Au nanoclusters to detect the tumour more rapidly than the 
dye molecules without severe accumulation in reticuloendothelial 
system organs.139 
Besides the above in vivo passive targeting, fluorescent metal 
35  nanoclusters can be tagged with bioactive molecules for targeting, 
imaging, and therapy. For example, Liu et al. synthesized 
fluorescent Au nanoclusters (0.92 ± 0.03 nm) using insulin as a 
template.113    The  resulting  Au-insulin  nanoclusters  retain  the 
insulin bioactivity and biocompatibility, and have been used to 
40  regulate the in vivo glucose level in Wistar rats. The results show 
isolated from the crude soot. One was short, tubular carbon, and 
the other a mixture of fluorescent nanoparticles derived from the 
SWCNTs. 
In 2006, Sun et al. obtained 5-nm non-fluorescent carbon dots 
75  via laser ablation of a carbon target, and then modified them with 
PEG to get fluorescent carbon dots with a fluorescence QY of 4% 
– 10%.142 The photoluminescence of these carbon dots was broad 
and  strongly  dependent  on  the  excitation  wavelength,  which 
could  be  attributed  to  the  different  sizes  in  the  sample  and 
80  different emission sites on the passivated particle surfaces. After 































Figure 13. Digital images of solid fluorescent carbon dots, 
aqueous solutions, and their absorption, excitation and 
emission spectra. Reproduced from Ref. 144. 
 
fluorescent  fractions  could  achieve  emission  yields  close  to 
60 %.143  Interestingly, their optical properties resemble band-gap
 
transitions,   which   are   found   in   nanoscale   semiconductors, 
suggesting that carbon dots have essentially semiconductor-like 
5  characteristics. Recently Bhunia et al. prepared hydrophobic and 
hydrophilic carbon dots with tuneable size and visible 
emissions,144 by dehydrating carbohydrate in octadecene in the 
presence of octadecylamine, or in concentrated sulphuric acid 
(Figure  13).  Their  method  produced  gram-scale  fluorescent 
10 carbon dots with a QY of 6 – 30%. Zhu and co-workers also 
reported  a  rapid  and  high-output  hydrothermal  approach  to 
prepare polymer-like carbon dots with QYs as high as 80 %.145
 
In addition to solid fluorescent carbon dots, there are some 
reports on hollow fluorescent carbon dots.146,  147  For example, 
15 Fang et al. simply mixed acetic acid, water and diphosphorus 
pentoxide to obtain cross-linked hollow fluorescent carbon 
nanoparticles. By reducing the release of heat, they also obtained 
solid fluorescent nanoparticles. So far, many approaches, such as 
arc-discharge,     laser     ablation,     electrochemical     oxidation, 
20 combustion/pyrolysis,    and    hydrothermal    and    microwave 
methods, have been developed to prepare solid and hollow 
fluorescent carbon dots.148 The preparation is inexpensive on a 
large  scale  without  the  need  for  stringent,  intricate,  tedious, 
costly, or inefficient steps.149 The recent advances in the synthesis 
25 and  characterization  of  fluorescent  carbon  dots  have  been 
reviewed.17, 148, 149 
The first study of fluorescent carbon dots in bioimaging was 
reported by the Sun group in 2007.150 The authors used poly- 
(propionylethylenimine-co-ethylenimine)    (PPEI-EI,    with    EI 
30  fraction ~20%) to modify the carbon dots, and then applied them 
to label human breast cancer MCF-7 cells. These labelled cells 
Figure  14.  (a)  NIR  images  of  mouse  bladders  acquired 
before and after injection of carbon dots through intravenous 
injection,  subcutaneous  injection,  and  intramuscular 
injection;  (b)  quantification  of  the  ZW800  fluorescence 
signal in (a); (c) representative coronal images from 1 h 
dynamic positron emission tomography (PET)   imaging. 
Reproduced from Ref. 152. 
exhibited   bright   fluorescence   in   both   cell   membrane   and 
cytoplasm regions under an excitation of 800-nm laser pulses. 
The   results   demonstrate   that   carbon   dots   exhibit   strong 
35  luminescence with two-photon excitation in the near-infrared, and 
moreover,  large  two-photon  absorption  cross-sections, 
comparable  to  those  of  available  high-performance 
semiconductor QDs.150 The authors further demonstrated the in 
vivo imaging of fluorescent carbon dots.151  They compared the 
40  imaging capability of carbon dots and ZnS-doped carbon dots, 
and  found  that  the  later  dots  emitted  more  strongly  than  the 
former dots both in solution and in mice. The fluorescence from 
the bladder area was observed, and 3 h after injection, the 
fluorescence could be detected in the urine, but it completely 
45 faded 24 h after injection. They analysed the biodistribution of 
carbon dots and found that the carbon dots accumulated in the 
kidney and, to a small extent, in the liver.151 This is attributed to 
the surface PEG, which likely reduces the protein adsorption. 
Recently  Huang  and  co-workers  investigated  the  effects  of 
50 injection routes on the biodistribution, clearance, and tumour 
uptake of carbon dots (Figure 14).152  They prepared fluorescent 
carbon dots through a laser ablation approach, and then 
functionalized carbon dots with the NIR dye ZW-800 and the 
isotope  64Cu.  They injected  the conjugates  into  mice  in  three 
55 different    manners,    i.e.    intravenous,    intramuscular,    and 
subcutaneous injection. The results show that  the carbon dots 
were efficiently and rapidly excreted from body after injection, 
and the clearance rate of carbon dots   decreased when the 
administration was varied from intravenous, to intramuscular, and 
60 then to subcutaneous injection (Figure 14). Different injection 
routes  also   showed   different   blood   clearance  patterns  and 
different tumour uptake of carbon dots. 
 
4.2 Fluorescent graphene quantum dots 
 
It  should  be  noted  that  fluorescent  graphene  quantum  dots 
65 (GQDs), the analogues of    carbon dots, have also attracted 
considerable attention.153, 154 Similar to carbon dots, GQDs can be 
prepared by top-down and bottom-up approaches, and their 
fluorescence can be enhanced via surface modification. The top- 






























Figure 15. (a) Image of GQD solution under UV-light; (b) 
schematic emissions in GQDs; (c-d) excitation-independent 
down-conversion and up-conversion spectra of GQDs; (e-f) 
excitation-dependent down-conversion and up-conversion 
spectra of GQDs. Reproduced from Refs. 155, 157, 160, and 
161. 
 
materials such as carbon nanotubes, graphene or graphene oxide 
sheets, and carbon fibres into small GQDs, through strong acid 
oxidation, hydrothermal or solvothermal treatment, or microwave 
and sonication treatment.154  For example, Zhu et al. dispersed 
5  graphene oxide in dimethyl formamide (DMF) under sonication, 
and then transferred the suspension into Teflon autoclaves and 
treated them at high temperature for a few hours to get GQDs 
with a QY of 11%.155, 156 Tetsuka and co-workers used the 
hydrothermal approach to treat graphene oxide sheets in ammonia 
10  solution to get GQDs with a QY between ~19 – 29%.157  The 
emission of GQDs can be tuned by controlling the hydrothermal 
temperature (Figure 15(a)), and the QYs can be further enhanced 
to ~46% after modification with PEG. Wu et al. used a one-step 
pyrolysis of a natural amino acid (i.e. glutamic acid) to prepare 
Figure  16.  Nitrogen-doped  GQDs  for  cellular  and  deep- 
tissue imaging. Reproduced from Ref. 164. 
 
30 was changed into blue after the GQDs were modified with 
alkylamines or reduced with NaBH4 (referred to as m-GQDs and 
r-GQDs respectively), while the particle size was similar. The 
fluorescence shift was attributed to the suppression of non- 
radiative  processes  and  to  the  enhanced  integrity  of  the  π 
35  conjugated system. These three types of GQDs exhibited strong 
excitation-dependent down-conversion and up-conversion 
emissions, demonstrated by that of the m-GQDs in Figure 15(e- 
f),155 which is in contrast to Zhuo’s report [Figure 15(c-d)]. In 
addition to the preparation, the optical properties of GQDs are 
40  also influenced by the solution pH, solvent, and concentration.154 
Recently, Xu et al. studied the fluorescence of GQDs on a 
substrate at the single particle level.160 All the GQDs investigated 
had the same spectral lineshapes and peak positions, despite 
notable  differences  in  particle  size  and  the  number  of layers. 
45  GQDs  with  more  layers  were  brighter  than  those  with  fewer 
layers, but were associated with shorter fluorescence lifetimes. 
Although there are some debates on the fluorescence 
mechanisms of GQDs, their unique properties afford many 
applications  in  cellular  and  deep-tissue  imaging.  Sun  and  co- 
50 workers demonstrated the first bioapplication of nanographene 
oxide (NGO),162 i.e., single-layer graphene oxide sheets a few 
nanometers in lateral width. The PEGylated NGO sheets used 
were soluble in buffers and serum without agglomeration, and 
showed photoluminescence in the visible and infrared regions. 
55  These NGO sheets had low background photoluminescence in the 
near-infrared (NIR) window. In addition, simple physisorption 
through π-stacking was used to load the anticancer drug 
doxorubicin onto NGO functionalized with antibody for selective 
162
 
15  fluorescent GQDs with a QY of 54.5%.158  Recently, Dong and 
co-workers used L-cysteine as precursor to prepare S,N-co-doped 
GQDs  with  a  QY  up  to  73%,159   which  is  the  highest  value 
reported so far. 
The  preparation  process  significantly  influences  the  optical 
20  properties of GQDs. There are two types of emissions in GQDs, 
killing of cancer cells in vitro. 
60  Compared with fluorescent carbon dots, GQDs can be used for 
two-photon or multi-photon luminescence imaging.163, 164 Qian et 
al. used PEGylated graphene oxide nanoparticles to label HeLa 
cells,163 and observed that graphene oxide nanoparticles were 
mainly  localized  in  the  mitochondria,  endoplasmic  reticulum, 
i.e. intrinsic state emission  and  defect state emissions  (Figure 
15(b)).160 The competition between these two states could be 
changed during preparation or post surface modification. For 
example, Zhuo and colleagues oxidized graphene in concentrated 
25  H2SO4 and HNO3, and then sonicated the mixture and calcinated 
it at 350 ˚C to remove acid.161  The resultant fluorescent GQDs 
did not exhibit excitation-dependent fluorescence [Figure 15(c- 
d)].161 However, Zhu et al. prepared green fluorescent GQDs 
through  the hydrothermal  approach.155   The  green  fluorescence 
65  Golgi apparatus, and lysosomes of HeLa cells with a two-photon 
scanning  microscope.   They  intravenously  injected   graphene 
oxide nanoparticles into mouse bodies from the tail vein, and 
observed their flow, distribution, and clearance in the blood 
vessels,    utilizing   a   deep-penetrating   two-photon    imaging 
70  technique. These nanoparticles were also injected into the brains 
of  gene  transfected  mice,  and  the  in  vivo  two-photon 
luminescence imaging results showed that graphene oxide 
nanoparticles  were  located  at  300  µm  depth  in  the  brain, 
 
 
demonstrating  the  advantage  of  QGDs  for  deep  imaging  in 
tissues. Recently, Liu et al. prepared nitrogen-doped GQDs as 
efficient two-photon fluorescent probes.164 These N-GQDs 
exhibited the highest two-photon absorption cross-section (up to 
5 48000 Göppert-Mayer units) among the carbon-based materials. 
They also demonstrated a large imaging depth of 1800 µm by a 
study of penetration depth in tissue phantom (Figure 16). 
In  summary,  surface-modified  fluorescent  carbon 
nanomaterials   (carbon   dots   and   GQDs)   have   small   size, 
10 distinctive photoluminescence properties, low toxicity, and low 
cost. These advantages offer them great potential for optical 
imaging and biomedical applications, as they might gradually 
replace conventional semiconductor QDs in these aspects. 
 
 
15  5 Ultra-small up-conversion nanocrystals 
 
Compared with previously mentioned fluorescent nanomaterials, 
up-conversion nanostructures, especially lanthanide-doped 
nanocrystals,  have  distinct  advantages  in  fluorescence 
bioimaging, such as low autofluorescence background, large anti- 
20 Stokes shifts, sharp emission bandwidth, high resistance to 
photobleaching, and high penetration depth and temporal 
resolution,165-171 In addition, they can be used for multimodal 
bioimaging and therapy (Figure 17). More bioapplications of up- 
conversion nanoparticles can be found in recent reviews.165, 169-171 
25  However,  they usually have  a  larger  size  in  comparison  with 
those nanoprobes described previously (i.e. QDs, metal 
nanoclusters, carbon dots, and GQDs). There are few reports on 
ultra-small up-conversion nanoparticles, especially those below 5 
nm.172-177  Herein we mainly introduce the fundamentals of up- 
30 conversion nanoparticles and the progress in preparation and 
imaging application of ultra-small nanoparticles. 
For  up-conversion  nanocrystals,  their  emission  process 
involves the sequential absorption of two or more photons, which 
is fundamentally different from the multi-photon process, where 
35  the absorption of photons takes place simultaneously. There are 
three types of up-conversion mechanisms, i.e. excited state 
absorption (ESA), energy transfer up-conversion (ETU), and 
photon avalanche.166 The up-conversion nanocrystals usually 
consist  of  activators,  sensitizers,  and  the  host  matrix  [Figure 
40  17(a)]. The activators should have more excited energy levels, 
and the energy difference between each excited level and the 
ground   level   should   be   close  enough   to   facilitate   photon 
absorption and energy transfer in the up-conversion process. 
Lanthanide ions such as Er3+, Tm3+, and Ho3+  have such ladder- 
45  like energy levels and are usually selected as activators. In order 
to  improve  the  luminescence  efficiency,  sensitizers  are 











Figure 17. (a) Schematic structure of multifunctional up- 
conversion nanoparticles; and (b) their potential applications 
in bioimaging and therapy. Reproduced from Ref. 165. 
 
activator  concentration,  and  accelerated  sensitizer-activator 
energy transfer rate arising from the decreased average minimum 
60 distance between adjacent lanthanide ions. The high brightness 
makes it possible to remotely track a single nanocrystal with a 
microstructured optical-fibre dip sensor.178 
Ideal host materials should have low lattice phonon energy and 
the  minimum  lattice  mismatch  with  dopants  (activators  and 
65 sensitizers). Rare-earth fluorides are generally chosen as host 
materials, as rare-earth ions have similar ionic size and chemical 
properties to lanthanide ions, and their fluorides exhibit low 
phonon energy and high chemical stability.166 In particular, 
NaGdF4 is extensively used as it can serve as a positive contrast 
70  agent  for  magnetic  resonance  imaging  (MRI).  Johnson  et  al. 
prepared four different sizes of β-NaGdF4  nanoparticles between 
2.5 nm and 8.0 nm.172 They found that the longitudinal relaxivity 
of nanoparticles increased from 3.0 mM-1s-1 to 7.2 mM-1s-1  with 
decreasing  particle  size  from  8.0  nm  to  2.5  nm.  The  authors 
75 doped Yb3+ and Tm3+ into β-NaGdF4 to form 3.5 nm particles, 
which exhibited an emission at 800 nm under the excitation of a 
980-nm laser.172 Their results highlight the importance of 
preparation of ultra-small nanoparticles in order to achieve large 
relaxivity for MRI. 
80  The   fluorescence   of  up-conversion   nanoparticles   can   be 
engineered through modulation of activators, sensitizers, host 
materials,  and  their  crystal  phase,  particle  size,  and  surface 
coating. Hasse and co-workers demonstrated the first example of 
multicolour emission of Yb3+/Er3+, and Yb3+/Tm3+  co-doped α- 
85  NaYF4  colloidal solution.
179  In 2008, Wang et al. developed a 
general and versatile approach to fine-tune the multicolour 
emissions  over  a  broad  range  with  single  wavelength 
excitation.180 By introducing Gd3+ during preparation, the authors 
simultaneously  controlled  the  crystal  phase,  particle  size,  and 
90  optical  properties  of  the  resultant  nanocrystals.181   Recently,  a 
core-shell structure with a set of lanthanide ions incorporated into 
separated layers was designed. The core-shell structure can 
minimize the deleterious effects of cross-relaxation. The bright 
3+
 
only one excited energy level (2F5/2), and the transition between up-conversion  emission  was  achieved  through  Gd mediated 
the ground level (2F7/2) and excited level is strongly resonant with 
50 many f-f transitions of lanthanide ions. The concentration of 
activators, and  the molar ratio between activators and sensitizers 
is usually kept low to avoid the quenching effect.166  Zhao et al., 
however, showed that up-conversion luminescence can be 
significantly    enhanced    by    using    much    higher    activator 
55  concentrations (e.g. 8  mol% Tm3+  in  NaYF4) under relatively 
high-irradiance  excitation.178   The  authors  attributed  the  high 
brightness to a combination of high excitation intensity, increased 
95  energy   migration    without   long-lived    intermediate    energy 
states.182, 183 
In up-conversion nanoparticles, minimizing the depletion of 
excitation energy is the key to tuning their luminescence. The 
excitation  energy  can  randomly  migrate  from  an  atom  to  its 
100 neighbouring atoms that are isotropically distributed in a 3D 
structured crystal sublattice (type I in Figure 18). This energy can 
also migrate in a crystal with a 2D layer structure (type II), or in a 
























Figure 18. Schematic illustration of the topological energy 
migration pathways in different types of crystal sublattice. 











Figure 19. Multifunctional upconversion nanoparticles for 
diagnosis and treatment of cancer through imaging-guided 
therapy. Reproduced from Ref. 186. 
 
Recently, Wang et al. proposed that migration of the excitation 
energy can be effectively minimized through use of a type IV 
(Figure 18) lattice containing arrays of isolated atomic clusters.184 
This  allows  to  minimize  the  concentration  quenching  of  the 
5 luminescence, and generates an unusual four-photon-promoted 
violet up-conversion emission from KYb2F7:Er (2 mol%) with an 
intensity more than eight times higher than that previously 
reported.184 The approach of enhancing up-conversion through 
energy  clustering  at  the  sublattice  level  may  provide  new 
10  opportunities to engineer up-conversion nanoparticles for diverse 
applications. 
The good understanding of the energy migration, luminescence 
mechanism, and the recent advances in wet chemistry have 
enabled the fine-tuning of particle size (even in the small size 
15 range),  crystal  structure,  surface  functionalities,  and  optical 
properties of up-conversion nanocrystals for bioimaging, drug 
delivery, and sensing.165, 167, 169  Their fluorescence has been 
applied to image cells and small animals.185 As mentioned 
previously, Gd-based up-conversion nanoparticles are particularly 
20  interesting  as  they  can  serve  as  fluorescent  nanoprobes  and 
contrast  agents  of  MRI  simultaneously.  Recently,  a 
multifunctional drug delivery system combining up-conversion 
luminescence/magnetic resonance/computer tomography 
trimodality   imaging   and   NIR-activated   platinum   pro-drug 
25  delivery  has  been  developed  by  Dai  and  co-workers  (Figure 
19).186                                       Organic-soluble                          core−shell 
Figure 20. Biodistribution of 5.1nm (NaGdF4) and 18.5nm 
(NaGdF4:Yb,Er) nanoparticles in different organs and tissues 




3+ nanoparticles were first 
prepared by complex thermal decomposition method, followed by 
surface  modification  and  conjugation  with  the  trans-platinum 
30 (IV) pro-drug. The up-conversion nanoparticles can not only 
deliver the platinum (IV) pro-drugs into the cells effectively, but 
convert near-infrared light into UV to activate pro-drug as well. 
Meanwhile, they can further serve as contrast agents for 
multimodality imaging to guide cancer treatment. The pro-drug- 
35 conjugated nanoparticles under near-infrared irradiation led to 
better inhibition of tumor growth than that under direct UV 
irradiation in the mouse test.186 Such multifunctional up- 
conversion   nanoparticles  have  been   a  subject   of  intensive 
research   due   to   their   potential   in   disease   diagnosis   and 
40  treatment.165, 170 
For in-vivo bioapplications, one of the major issues for up- 
conversion nanocrystals is the fate of nanoparticles and potential 
toxicity of lanthanide ions.187, 188 Liu et al. prepared 5.1 nm 
NaGdF4 and 18.5 nm NaGdF4:Yb/Er nanoparticles with the same 
45  surface  modification  and  investigated  their  biodistributions  in 
different organs and tissues of mice (Figure 20).189 The 
accumulation of both types of nanoparticles in liver decreased 
with the circulation time. In contrast, their accumulation in spleen 
increased with the circulation time. This suggests that both of 
50  these  nanoparticles  may   be  eliminated   through   the   biliary 
pathway. Analysis of urine collected at different time points 
indicates that renal clearance was one of the major elimination 
pathways for 5.1-nm particles, but not for 18.5-nm particles. 
Further analysis on faces by TEM shows that these particles do 
55  not change in shape and size, suggesting the high stability of up- 
conversion nanoparticles in vivo.189 
Although up-conversion nanoparticles do not show acute 
toxicity at the cell or animal level, it is necessary to investigate 
their  long-term  toxicity.  Another  drawback  of  up-conversion 
60  nanocrystals is the low quantum yield (usually less than 1%) in 
comparison  with  other  fluorescent  agents.165    Preparation  of 




65  6 Fluorescent silicon nanoparticles 
 
Fluorescent silicon nanoparticles (Si NPs) have also attracted 
considerable attention in bioapplications due to their excellent 






















Figure 21. (a) Silicon nanoparticle fractions under ambient 
light and under photoexcitation at 365 nm; (b-c) size- 
dependent  absolute  QYs  of  Si  nanoparticles.  Reproduced 
from Ref. 191. 
trace element.18, 20, 190  More importantly, they have tunable 
fluorescence  from  visible  to  near-infrared  window.  Compared 
with other semiconducting QDs, the preparation of high-quality 
water-soluble   and   biocompatible   Si   QDs   is   devious   and 
5  laborious.  Colloidal  Si  NPs  are  conventionally  prepared  by 
etching  annealed  SiOx    with  HF,  plasma  approach, 
electrochemical method, laser ablation, reduction of SiCl4, and 
solvothermal  reaction  of  sodium  silicide  with  NH4Br.
18,  190-193
 
These Si NPs are usually functionalized with hydrophobic ligands 
10  such  as  styrene,  alkyl,  and  octene.  They  are  photochemically 
stable in non-polar solvents up to 1 year.192  For example, high- 
temperature thermal processing of the sol-gel precursor derived 
from trichlorosilane (HSiCl3) produced Si NPs embedded within 
the SiO2 matrix.
191, 194 Si NPs were released after etching the SiO2 
15  matrix with HF, and then passivated with allylbenzene through 
the thermally initiated hydrosilylation reaction. The resultant 
colloidal Si NPs were fractionated by size selective precipitation 
to obtain monodisperse nanoparticles, which showed strong 
quantum confinement effects and size-dependent absolute QYs 
20  (Figure 21).191  The absolute QYs increased with particle size up 
to 43%. 
During preparation, Si NPs can be chemically doped to 
introduce other functions.195, 196 Paramagnetic fluorescent Si NPs 
were  prepared  by  solvothermal  decomposition  of  Mn-doped 
25  sodium  silicide.195   The  resultant  Mn-doped  Si  NPs  showed  a 
longitudinal  relaxivity  (r1)  of  25.50  ±  1.44  mM
























Figure 22. (a) Photostability of Si NPs in comparison with 
FITC, CdTe QDs and CdSe/ZnS QDs; (b) cell nuclei are 
labeled by Si NPs (Left), microtubules are labeled by FITC 
(middle); and superposition of the two fluorescence images 
(right); (c) time-dependent stability comparison of 
fluorescence signals of Hela cells labeled by Si NPs (blue) 
and FITC (green). Reproduced from Ref. 204. 
 
somewhat independent of particle size.197, 198  Recently, Dasog et 
40  al. prepared Si NPs using three most widely cited procedures (i.e. 
etching of annealed SiOx, reduction of SiCl4, and solvothermal 
197
 
transverse  relaxivity  (r2)  of  89.01  ±  3.26  mM
-1s-1   under  a reaction  of  sodium  silicide  with  NH4Br), and  found  their 
magnetic field of 1.4 T at 37 °C. Similarly, Fe-doped Si NPs were 
prepared and exploited as bimodal imaging agents.196 The use of 
30  reactive sodium silicide makes their control preparation difficult 
and could limit their broad applications, and thus development of 
novel preparation approaches is necessary. 
Similar  to  carbon  dots  and  GQDs,  Si  NPs  produced  from 
different methods seem identical, but their optical properties are 
35 dramatically different. For example, the Si NPs prepared with 
high-temperature method routinely exhibit photoluminescence 
agreeing with the effective mass approximation (EMA), while 
those  prepared  via  solution  methods  exhibit  blue  emission 
conversion of red-fluorescence to blue emission. Their findings 
suggest that the presence of trace nitrogen and oxygen even at the 
45  ppm level in Si NPs gives rise to the blue emission, and support 
the hypothesis that the nitrogen defect or impurity site contributes 
to the blue emission.197 
In order to apply Si NPs to bioimaging, tremendous efforts 
have been made to prepare water-soluble and biocompatible Si 
50  NPs through simple and efficient methods.199-205 For example, Si 
NPs with excellent aqueous dispersibility, robust photo- and pH- 
stability, strong fluorescence (∼15%), and favorable size (∼4 nm)
 
are facilely and rapidly prepared from Si nanowires and glutaric 
 
 
acid in a short reaction time (e.g., 15 min) by He and co- 
workers.202  These Si NPs are particularly suitable for long-term 
and real-time cellular imaging due to their higher photostability 
than II-VI QDs and dyes (e.g. CdTe QDs and FITC). Distinctive 
5  red fluorescence of Si NPs can be retained throughout 240-min 
irradiation. In contrast, the green fluorescence of FITC rapidly 
diminishes in 3 min due to severe photo bleaching, and the red 
signals of CdTe QDs nearly vanishes after 25-min irradiation. 
The  MTT  assays  showed  negligible  cellular  toxicity  to  HeLa 
10 cells, demonstrating the excellent biocompatibility of Si NPs. 
Furthering their research, the authors used (3- 
aminopropyl)trimethoxylsiliane as precursor and prepared 2.2 nm 
Si NPs by the similar method.204  The obtained Si NPs exhibited 
strong    green     fluorescence     with     a     QY     of    20-25%, 
15  biocompatibility, and robust photo- and pH-stability. As shown in 
Figure 22, FITC, CdTe and CdSe/ZnS QDs, and Si NPs exhibited 
distinct fluorescence behaviors during initial UV irradiation.204 
The  fluorescent  signals  of  the  former  three  samples  were 
gradually   reduced   with   increasing   irradiation   time.    The 
20 fluorescence of FITC was completely quenched within 15 min 
irradiation. In contrast, the Si NPs preserved stable and bright 
fluorescence during long-time (e.g., 180 min) irradiation under 
the same conditions. Figure 22c also shows that Si NPs-labelled 
nuclei (blue) and the FITC-labelled cellular microtubules (green) 
25  were intense and clearly spectrally resolved, respectively. The Si 
NP-labelled  nuclei  retained  stable  fluorescence  during 
observation for 60 min, however the fluorescence from FITC 
labels drastically decreased in 3 min due to severe photo 
bleaching. 
30  In addition to in vitro labelling cells, Si NPs can also be used 
in multiple cancer-related in vivo applications, including tumor 
vasculature targeting, sentinel lymph node mapping, and 
multicolor   NIR   imaging   in   live   mice.206     Erogbogbo   and 
coworkers demonstrated that Si NPs can overcome dispersibility 
35 and functionalization challenges for in vivo imaging through 
surface functionalization, PEGylated micelle encapsulation, and 
bioconjugation process, which produced bright, targeted 
nanospheres with stable luminescence and long (>40 h) tumor 
accumulation  time  in  vivo.  Recently,  the  biodistribution  and 
40  toxicity  of  Si  NPs  in  mice  and  monkeys  have  been  assessed 
(Figure 23).207 The top images in Figure 23 show the 
biodistribution  of  Si  NPs  in  mice,  the  fluorescence  image  of 
frozen tissue sections, and the confocal images, which clearly 
reveals particles localized in the liver, spleen, and kidneys after 
45  injection.  The  ICP-MS  data  show  notable  increase  of  silicon 
levels in the liver, spleen, lung, kidneys, and lymph. The 
concentration of silicon in the lymph and kidneys declined over 
the 14-week time period, while the liver and spleen retained a 
significant fraction of the silicon injected, even after 14 weeks.207 
50  There is no evidence of the biodegradability of silicon NPs. The 
bottom images in Figure 23 display the histological images of the 
brain, cerebellum, atrium, ventricle, heart muscle, lung, kidney, 
liver, spleen, renal tubule, intestine, lymph nodes, and skin of the 
rhesus macaques.207  There was no sign of nanoparticle-induced 
55  changes  in  these  organs  and  tissues.  This  research  indicates 
neither  mice  nor  monkeys  showed  overt  signs  of  toxicity 
reflected in their behavior, body mass, or blood chemistry. The 





Figure 23. (Top) biodistributions of Si NPs in mice assessed 
by ICP-MS analysis, fluorescence images of frozen tissue 
sections, confocal microscopy images; (bottom) histological 
images of (a) brain, (b) heart, (c) liver, (d) spleen, (e) lung, (f) 
kidney, (g) lymph, (h) intestine, and (i) skin harvested from 
rhesus  macaques  administrated  with  Si  NPs.  Reproduced 
from Ref. 207. 
evaluated  by  in  vivo  positron  emission  tomography  (PET) 
60  imaging  and  ex  vivo  gamma  counting.208   A  new  macrocyclic 
ligand-64Cu2+   complex  was  conjugated  with  dextran-coated  Si 
NPs and served as PET agent. The results show that conjugates 
were excreted via renal filtration shortly post injection and also 
accumulated in the liver, again demonstrating the stability and 
65  biocompatibility of Si NPs. 
In summary, Si NPs have tuneable fluorescence from visible to 
near-infrared window, excellent biocompatibility, chemical, and 
photostability. These properties make them very attractive in 
bioimaging,  however  long-term  studies  on  their  safety  and 
70  adverse effects are still needed for their clinical applications. 
 
7 Summary and outlook 
 
We have summarized the current state of the art on ultra-small 
inorganic nanoparticles for fluorescence bioimaging. These ultra- 
small  nanoparticles  bridge  the  gap  between  big  particles  and 




molecular imaging for  diagnosis  and  treatment of  cancer and 
other diseases, as they could escape from macrophages, pass 
biological barriers, and be easily degraded or excreted in 
comparison with large particles. 
5  The ultra-small fluorescent probes we addressed include the 
conventional QDs, fluorescent metal nanoclusters, carbon-based 
nanomaterials, up-conversion nanocrystals, and silicon 
nanoparticles.  The  fluorescence  mechanisms  in  metal 
nanoclusters, carbon dots, and graphene quantum dots are not 
10  completely  clear  as  yet.  Although  they  can  be  prepared  by 
various wet chemistry methods, it remains a challenge to prepare 
robust fluorescent probes with high photostability (i.e. non- 
blinking), chemical stability, high quantum yield, and tunable 
emissions in the visible to NIR window. From the applications 
15 perspective, some of them face the issue of toxicity, especially 
semiconducting  QDs  and  up-conversion  nanocrystals,  as  they 
have toxic elements such as cadmium and lanthanides. Various 
approaches and coatings have been developed to modify and 
functionalize their surfaces to overcome these shortcomings. In 
20  addition to the issues of fluorescent nanoprobes themselves, there 
are some important issues that have to be considered for practical 
applications, including their interactions with proteins and other 
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biomolecules, their interactions with cells, their endocytosis and 
intracellular stability and behaviour, and their metabolism and 
25 excretion. These issues have not been well understood, despite 
some progresses on bio-interface interactions in the biological 
environments have been made in recent years.61-63 
The use of fluorescence imaging alone could lead to inaccurate 
diagnosis or misdiagnosis, due to the low spatial and temporal 
30 resolution,  and  the  sensitivity  of  fluorescence  to  external 
environments. Simultaneous use of multi-modal imaging (e.g. 
magneto-fluorescence) could overcome the disadvantages of 
individual methods. There are increasing reports on the 
combination of fluorescence with other imaging methods such as 
35  MRI,   CT,   and   PET.60,    209-212    There   are   few   commercial 
multifunctional instruments for multimodal imaging, however. 
Relocating biological samples between different imaging 
instruments could lead to inaccuracy.213 Development of 
multimodal  imaging  that  employs  a  single  instrument  is  an 
40  attractive solution.213  In addition, incorporation of therapeutics 
into multimodal nano-agents for early detection and treatment 
will be an important feature of future nanotheranostics. 
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